Business & Finance

Cancer drug developer reports loss of $0.23 per share

Published in Cancer Weekly, February 28th, 2006

Array BioPharma, Inc., (ARRY) reported financial results for the second quarter of fiscal 2006.

For the second quarter of fiscal 2006, Array reported revenue of $11.9 million, compared to revenue of $12.0 million for the same period in fiscal 2005. Investment in research and development for proprietary drug discovery was $7.8 million, a $2.5 million increase over the same quarter last year, due to additional preclinical and clinical development.

Array reported a net loss of $8.7 million, or $0.23 per share, for the second quarter, compared to a net loss of $4.9 million, or $0.16 per share, for the same quarter in fiscal 2005. The reported net loss...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-02-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry